The Neonatal Respiratory Distress Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Neonatal Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neonatal Respiratory Distress Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neonatal Respiratory Distress Syndrome and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Neonatal Respiratory Distress Syndrome by five companies/universities/institutes. The top development phase for Neonatal Respiratory Distress Syndrome is preclinical with six drugs in that stage. The Neonatal Respiratory Distress Syndrome pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Neonatal Respiratory Distress Syndrome pipeline products market are: Chiesi Farmaceutici, Bill & Melinda Gates Medical Research Institute and VGSK Technologies.
The key targets in the Neonatal Respiratory Distress Syndrome pipeline products market include Glucocorticoid Receptor.
The key mechanisms of action in the Neonatal Respiratory Distress Syndrome pipeline product include Glucocorticoid Receptor Agonist with one drug in Preclinical. The Neonatal Respiratory Distress Syndrome pipeline products include three routes of administration with the top ROA being Inhalational and four key molecule types in the Neonatal Respiratory Distress Syndrome pipeline products market including Recombinant Protein, and Small Molecule.
Neonatal Respiratory Distress Syndrome overview
Neonatal respiratory distress syndrome, or RDS, is a common cause of respiratory distress in a newborn, presenting within hours after birth, most often immediately after delivery. It usually affects preterm neonates and term infants. The incidence of RDS is inversely proportional to the gestational age of the infant, with more severe disease in the smaller and more premature neonates. Treatment modalities include antenatal corticosteroids, surfactants, and advanced respiratory care of the neonate, and though they have improved the outcomes for patients affected by RDS, it continues to be a leading cause of morbidity and mortality in the preterm infant.
For a complete picture of Neonatal Respiratory Distress Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
